0.5-1.0 mmol/I,40-45 although increases of up to 2 mmol/l have been reported. 41 Increasing the dose of suxamethonium has been found to increase the rise in serum potassium slightly,9 or not at all. 8, 49 The increase lasts up to an hour in experimental animals,5° but usually less than 10-15 minutes in humans. 4o -45 Similar potassium changes have been found following succinylmonocholine, a metabolite of suxamethonium 5o ,51 and decamethonium. 2o , 43 Plasma potassium did not increase after suxethonium in one study, 52 The potassium originates from skeletal muscle and is thought to be liberated by depolarisation at the neuromuscular junction, causing movement of potassium across the post-synaptic membrane. 43 ,53,54 It may also be released from muscle fibres damaged by the incoordinate contractions induced by suxamethonium, since raised blood levels of creatine kinase and myoglobin may occur following use of the drug, 46, 55, 56 Factors affecting the increase in potassium Decreases in potassium levels may be seen after induction of anaesthesia with thiopentone, Althesin, ketamine, propranidid, nitrous oxide and halothane, but not etomidate. 42.57-64 The suxamethoniuminduced increase may be greater after induction with nitrous oxide, or with halothane or trichloroethylene, than with intravenous agents, 42.57,59,64 One study has shown attenuation of the increase during ether anaesthesia, but there was no control group. 65 The effects of enflurane and isoflurane on the potassium response to suxamethonium have not been studied. The increase may be enhanced by respiratory acidosis,66 and decreased by alkalosis. 67 Complete or partial attenuation of the  hyperkalaemic response to suxamethonium  has been achieved by pre-treatment with  tubocurarine 17 ,19,20,56,59,68,69 (but not  al ways 49,70), gallamine,5o,71 pancuronium,72  fazadinium,73 suxamethonium,74 67 In dogs, beta-blockade delayed the suxamethonium-induced increase in potassium;80,84 it also caused a greater rise in one study,80 but not in another. 84 A study in humans found no effect of beta blockade, but plasma potassium was only measured for six minutes after administration of suxamethonium. 85 Verapamil has been found to have no effect on the suxamethoniuminduced potassium increase. 86 Conditions in which the increase in potassium is exaggerated Mechanism
Recommendations of several recent textbooks on avoidance of suxamethonium following burns or denervating/spinal cord injury
Originally, it was thought that cardiac arrest following suxamethonium resulted from increased vagal tone, since sinus and nodal bradycardia had already been shown to occur after single, and especially repeated, doses of suxamethonium. 87 However, it soon became clear that burns patients showed an exaggerated potassium increase in response to suxamethonium, and that cardiac arrest was accompanied by severe acute hyperkalaemia. 5 -9 A similar response was subsequently found in patients with spinal cord lesions 1°-18 and some other neurological conditions. 10, 17, 18, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In burns, upper and lower motor neurone lesions, and presumably the other conditions in which exaggerated hyperkalaemia occurs, there is proliferation of post-synaptic acetylcholine receptors beyond the area of the neuromuscular junction, beginning a few days after injury. 18,53,88-90 Potassium movement across the muscle membrane is then no longer confined to the neuromuscular junction, with the result that plasma potassium increases more than it does in normal subjects. 18, 53, 88, 89 Associated disuse of the muscle may contribute to this response. 91 Review of the literature Direct comparison between case reports and studies is difficult because of differences in practical and analytical details. For example, typical electrocardiographic (ECG) features of hyperkalaemia (tall peaked T waves, absent P waves, widened QRS complexes, slurring of ST segments into T waves) are usually accompanied by ventricular arrhythmias, including fibrillation, at potassium levels above 7 mmol/l. 92 However, in many of the earlier reports, ECG monitoring was not used, and details are therefore sketchy.l,2,15,31,93-95 It is possible that suxamethonium-induced bradycardia was indeed the cause of cardiovascular collapse in some instances, because potassium levels were not always measured. 1-4,93-98 In addition, the interval between injury and anaesthesia is not mentioned in some papers. 1,2,4,93,95 Finally, cardiac arrests and deaths during surgery have been reported in a number of burns and trauma patients without the use of, or mention of, suxamethonium. The cause is often uncertain due to the lack of details supplied. 1,2,93,95
Burns
Cardiac arrest or ECG changes as described above have been reported at many intervals after thermal injury, although often without measurement of plasma potassium. 1,3,5,93-99 The shortest period after burns was twentyone days,96 and the longest was fifty-one days. 99 In other studies, some of which involved cardiac arrest or ECG changes, serum potassium levels were measured in more than 120 patients at different periods after burns. 6 -9 An exaggerated potassium increase occurred at nine days in one case,6 with normal responses occurring up to 14-20 days in the remaining patients. 6 -9 Exaggerated hyperkalaemia occurred up to 60-66 days, with normal responses thereafter. 8 ,9
The study by Birch et al. 7 is of particular interest, since it included measurement of the sequential serum potassium changes in two patients undergoing repeated anaesthesia following severe burns. An increased potassium response was seen after 14 days in one patient (although only a 1.1 mmol/l rise), and after 16 days in the other. In both patients, increases of over 3 mmol/l occurred during subsequent anaesthetics.
From these studies and case reports, it can be concluded that an abnormal hyperkalaemic response is unlikely before 14 days after burns, as it has been reported only once: at nine days.6 There is therefore no evidence to suggest avoidance of suxamethonium before at least seven days and even this value is based upon speculation that there would have been a lesser, but still dangerous, increase in potassium at, say, eight days. Excessive hyperkalaemia has occurred up to 66 days after burns, 8 but there are no reports of an abnormal response after this time.
The magnitude of the potassium increase was proportional to the extent of burns in two studies. 6 . 9 Neurological conditions Many neurological disorders have been investigated, often being grouped together without specifying individual diseases;17 thus precise analysis is sometimes difficult. Each condition will be considered in turn.
Spinal cord injury. As with burns, there
have been many reports of cardiac arrest and hyperkalaemia following suxamethonium in patients with traumatic spinal cord lesions and para-or tetraplegia. lo . 17 The earliest clinical report of severe hyperkalaemia is at 21 days after spinal cord injury,IO with the other reports between 23 and 75 days.II.17 Normal responses are reported after six months, although details are not given in this study.17 Experimental work has shown the time of onset of the exaggerated response to be ten days after cord transection in rats. 66 In dogs, a significantly increased response is not seen until 14 days, with peak increases of 2.7 mmolll at 28 days. 100 suxamethonium administration seven months after craniotomy for medulloblastoma. 26 In another study, no potassium increase at all was found in fifteen patients with brain tumours causing unilateral weakness or paresis of 2-120 days duration. 35 3. Peripheral nerve injury. In 23 patients with peripheral nerve injuries, potassium in blood draining the affected limb increased by more than 4.0 mmolll after suxamethonium, compared with an increase of less than 0.7 mmolll in blood draining the other limb. 19 The age of the injuries ranged from 22 to 192 days.
Upper motor neurone lesions and
An abnormal arm contracture following suxamethonium was associated with an increase in serum potassium in the affected limb from 3.8 to 6.1 mmolll, 42 days after brachial plexus injury affecting C5 and C6. 101 Prolonged arm contracture has also been reported in a patient with a Pancoast tumour affecting C5/6, although serum potassium was not measured. 102 In animal studies, the onset of an increased potassium response occurred four days after denervation injury in baboons, with a peak increase at fourteen days.l03 In rats, the peak increase occurred at 18-22 days,51 while in dogs, it occurred at 28 days, although it was first seen at 14 days, and was still greater than 1.4 mmolll at 56 days. 100
Thus the experimental work would suggest four days as the period after injury during which suxamethonium may be used safely, although there is no human data to support this. The longest interval after which an abnormal response to suxamethonium has been reported is 192 days. 19 4. Peripheral neuropathy. There are reports of cardiac arrest and hyperkalaemia occurring after administration of suxamethonium to patients with diffuse lower motor neurone neuropathies. In four who had suffered progressive neuropathy for more than five months, potassium was not measured during their cardiac arrests. 36 In another, plasma potassium rose from 3.8 to 7.9 mmolll, 61 days after onset of symptoms. 37 A level of 4.5 mmolll was measured in a patient with renal failure and peripheral neuropathy after a single dose ofsuxamethonium, with a level of7.3 mmolll after a second dose. 38 One would expect the increased risk of hyperkalaemia to be continuous in progressive peripheral neuropathies, but otherwise similar to that of peripheral nerve injuries. Hyperkalaemia following suxamethonium in patients with motor neurone disease has not been reported, although it might be expected. 5. Parkinson's disease. There is one case report in which a potassium level of 7.6 mmolll was measured after suxamethonium infusion in a patient with Parkinson's disease; the patient was moribund with severe myocardial infarction and pulmonary oedema, and had had previous spinal surgery. 104 Parkinson's disease was included in Cooperman's study of neuromuscular disease and suxamethonium,17 but its relationship with hyperkalaemia is not clear. to suxamethonium has been shown in patients with thoracic or lumbar myelomeningocele lll and in patients with cerebral palsy; 112 in both studies the neurological deficits had been present for more than one year. Cardiac arrest and massive hyperkalaemia following suxamethonium has occurred in a patient with cerebral palsy, but this was at 37 and 41 days after subarachnoid haemorrhage. 31 Patients with paraplegia, multiple sclerosis, muscular dystrophy, Parkinson's disease, brain tumours and strokes were investigated for hyperkalaemia following administration of suxamethonium. 17 The period of risk was stated to be longer in the progressive diseases, but details of individual disorders and their responses are lacking. The magnitude of potassium increase described by Cooperman was proportional to the extent of neurological deficit.17 This was not found after subarachnoid haemorrhage,30 but in dogs with transected peripheral nerves, the increase was proportional to the volume of denervated muscle. 100 Trauma An increased hyperkalaemic response has been reported in patients with severe trauma, related to the time since injury.20 The injuries included burns, gunshot wounds and open fractures, but the distribution and severity of the injuries and the time between injury and suxamethonium administration were not stated. Another study reported increased responses in patients with 'peripheral' war injuries; again, details of type and severity of wound were not supplied. 21 Whether the patients had been burnt or were infected (see below), was also not stated. The earliest exaggerated potassium increase (of 1.5 mmol/l) occurred ten days after the injury, with the largest increases (3-6 mmolll) after 30-40 days. An increase of 1.3 mmol/l was measured after 155 days, with an increase of 0.7 mmol/l after 165 days.
Similar results were found in a study that included major trauma and burns. Increases of up to 7.0 mmol/l were measured. 7 Other reports have described marked suxamethonium-induced hyperkalaemia occurring after muscle necrosis due to the following: (a) radiation: excessive suxamethoniuminduced hyperkalaemia occurred 21 days after radiation injury to leg muscle in rats. This study was prompted by the occurrence of a cardiac arrest following suxamethonium in a patient treated with radiotherapy to a leg sarcoma;22 (b) extreme hypothermia: the patient was cooled for eight days following cardiac surgery; administration of suxamethonium six days later was followed by excessive hyperkalaemia. 23 However, this explanation has been disputed; 113 (c) severe rhabdomyolysis due to the neuroleptic malignant syndrome; marked hyperkalaemia followed administration of suxamethonium fifteen days after mechanical ventilation was required. 24 The increased hyperkalaemic response to suxamethonium in trauma may thus be related to direct damage to muscle, in addition to any associated muscle denervation or burns.
Infection
Following suxamethonium, a potassium increase of greater than 2.5 mmolll was reported in four out of nine patients with abdominal infection, in some cases leading to cardiac arrest. I 14 The authors suggest that the risk of hyperkalaemia is increased if infection is severe and of more than seven days' duration.
In another series, potassium increases of 0.6-2.3 mmolll were found in 21 patients with osteomyelitis, gangrene or abscesses, compared with increases of less than 0.5 mmolll in 21 controls. I 15 The potassium increase was related to the severity of infection and to its duration, up to the 21 days studied.
Cardiac arrest was recently reported in a patient with severe intra-abdominal sepsis of 17 days' duration, associated with a potassium increase from 4.2 to 9.9 mmolll following suxamethonium. 116 There is also a report of severe hyperkalaemia occurring in a patient after 31 days' infection of bilateral amputation stumps.117
Uraemia
In eleven out of twelve patients with renal failure, potassium increases of less than 0.7 mmolll were measured, with an increase of 1.2 mmolll in the remaining patient. 118 Other studies have shown normal responses in humans with renal failure70.119 and acutely uraemic monkeys,120 although an increase of 1.7 mmolll was measured in one chronically uraemic monkey in another study,121 and an exaggerated increase was found in uraemic rats. 122 Although severe hyperkalaemia has occurred after suxamethonium in patients with chronic renal failure,38.123 it is now considered that suxamethonium may be safely given unless there is associated neuropathy, or if pre-induction serum potassium is even slightly raised, since even a small, i.e. 'normal' increase may then produce dangerous levels. 70 ,119.124.125 In most of the reported cases of cardiac arrest following s uxamethoni urn, resuscitation was successful, using external cardiac massage, defibrillation and intravenous calcium. Indeed, some patients who underwent repeated anaesthetics suffered cardiac arrests on more than one occasion in the weeks following injury, and were successfully resuscitated each time. 1,4,5,7,13,31,94,97·99 CONCLUSION The underlying mechanisms behind the acetylcholine receptor proliferation, and whether they are the same for all the conditions mentioned above, are unclear. From the case reports and studies reviewed, there would appear to be four groups of conditions in which hypersensitivity to suxamethonium may exist, with differing periods of risk: (i) burns; nine days until just over two months. (ii) upper motor neurone lesions, trauma and spinal cord lesions; ten days until six to seven months. (iii) peripheral denervation; four days until six to seven months. (iv) continuing processes, such as neuropathies, tetanus, infection; seem to present a continuing period of risk after about seven days. The period of maximum risk in most studies begins at around fourteen days.
It is impossible to state categorically that the risk of severe hyperkalaemia in response to suxamethonium is present on one day and not on the next. It might be argued that where there is any doubt as to the safety of suxamethonium it is better avoided completely. Against this must be weighed the advantages of suxamethonium for tracheal intubation, compared with the advantages and disadvantages of other drugs and techniques available. The ultimate decision whether to use suxamethonium for an individual patient will thus depend on the particular circumstances involved in that case.
